Trial Outcomes & Findings for Domperidone in Refractory Gastroparesis (NCT NCT00760461)
NCT ID: NCT00760461
Last Updated: 2017-08-18
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
44 participants
Primary outcome timeframe
upon study completion
Results posted on
2017-08-18
Participant Flow
Participant milestones
| Measure |
Domperidone
Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
|
|---|---|
|
Overall Study
STARTED
|
44
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
44
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Domperidone in Refractory Gastroparesis
Baseline characteristics by cohort
| Measure |
Domperidone
n=44 Participants
Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
|
|---|---|
|
Sex: Female, Male
Female
|
35 Participants
n=44 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=44 Participants
|
PRIMARY outcome
Timeframe: upon study completionPopulation: Data cannot be summarized or analyzed due to the lack of data being collected on the primary outcome due to the trial being terminated.
Outcome measures
Outcome data not reported
Adverse Events
Domperidone
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place